| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Nephrology and Transplantology, Department of Endocrinological Gynecology, Medical University, 15-540 Bialystok, Zurawia 14, Poland
Address all correspondence and requests for reprints to: Jolanta Malyszko, Department of Nephrology and Transplantology, Medical University, 15-540 Bialystok, Zurawia 14, Poland. E-mail: jolmal{at}poczta.onet.pl.
Adiponectin has antiatherogenic properties and attenuates endothelial inflammatory responses. CD146 is a novel cell adhesion molecule localized at the endothelial junction. In renal failure, endothelial dysfunction and atherosclerosis are almost universal. We studied possible correlations between adiponectin, CD146, and other markers of endothelial cell injury in patients with chronic renal failure (CRF) on conservative treatment and patients with and without diabetic nephropathy maintained on chronic ambulatory peritoneal dialysis (CAPD).
We assessed adiponectin, tissue factor pathway inhibitor (TFPI), plasminogen activator inhibitor (PAI-1), thrombin-activatable fibrinolysis inhibitor, and endothelial function/injury markers: von Willebrand factor, thrombomodulin, vascular cell adhesion molecule (VCAM), intercellular adhesion molecule, and CD146.
Adiponectin was elevated in patients with CRF and on CAPD. It correlated significantly, with PAI-1, thrombin-activatable fibrinolysis inhibitor, intercellular adhesion molecule, VCAM, and CD146 in nondiabetics on CAPD. In diabetics, CAPD adiponectin correlated positively with C146 and VCAM and negatively with PAI and TFPI. In multivariate regression analysis, only CD146 remained a positive predictor of adiponectin in all CAPD patients. In CRF, adiponectin correlated with CD146. In healthy volunteers, adiponectin correlated with TFPI and CD146.
Elevated adiponectin related to CD146 may be the expression of a counterregulatory response aimed at mitigating the consequences in endothelial damage and increased cardiovascular risk in renal failure.
This article has been cited by other articles:
![]() |
J. Malyszko, J.S. Malyszko, P. Kozminski, K. Pawlak, and M. Mysliwiec Adipokines, Linking Adipocytes and Vascular Function in Hemodialyzed Patients, May Also Be Possibly Related to CD146, a Novel Adhesion Molecule Clinical and Applied Thrombosis/Hemostasis, July 1, 2008; 14(3): 338 - 345. [Abstract] [PDF] |
||||
![]() |
M. I. Yilmaz, M. Saglam, J. J. Carrero, A. R. Qureshi, K. Caglar, T. Eyileten, A. Sonmez, E. Cakir, M. Yenicesu, B. Lindholm, et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease Nephrol. Dial. Transplant., March 1, 2008; 23(3): 959 - 965. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Pilz, H. Mangge, B. Wellnitz, U. Seelhorst, B. R. Winkelmann, B. Tiran, B. O. Boehm, and W. Marz Adiponectin and Mortality in Patients Undergoing Coronary Angiography J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4277 - 4286. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nishimura, T. Hashimoto, H. Kobayashi, S. Yamazaki, K. Okino, H. Fujita, N. Inoue, H. Takahashi, and T. Ono Association of the circulating adiponectin concentration with coronary in-stent restenosis in haemodialysis patients Nephrol. Dial. Transplant., June 1, 2006; 21(6): 1640 - 1647. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. G. Schalkwijk, N. Chaturvedi, M. T. Schram, J. H. Fuller, C. D. A. Stehouwer, and the EURODIAB Prospective Complications Study Group Adiponectin Is Inversely Associated with Renal Function in Type 1 Diabetic Patients J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 129 - 135. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |